Elliott Vichinsky1, Lynne Neumayr, Sean Trimble, Patricia J Giardina, Alan R Cohen, Thomas Coates, Jeanne Boudreaux, Ellis J Neufeld, Kristy Kenney, Althea Grant, Alexis A Thompson. 1. Children's Hospital Oakland, Oakland, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Weill Medical College of Cornell University, New York, New York; Children's Hospital Philadelphia, Philadelphia, Pennsylvania; Children's Hospital Los Angeles, Los Angeles, California; Children's Healthcare of Atlanta at Scottish Rite, Atlanta, Georgia; Boston Children's Hospital, Boston, Massachusetts; Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.
Abstract
BACKGROUND: Transfusions are the primary therapy for thalassemia but have significant cumulative risks. In 2004, the Centers for Disease Control and Prevention (CDC) established a national blood safety monitoring program for thalassemia. This report summarizes the population and their previous nonimmune and immune transfusion complications. STUDY DESIGN AND METHODS: The CDC Thalassemia Blood Safety Network is a consortium of centers longitudinally following patients. Enrollment occurred from 2004 through 2012. Demographics, transfusion history, infectious exposures, and transfusion and nontransfusion complications were summarized. Logistic regression analyses of factors associated with allo- and autoimmunization were employed. RESULTS: The race/ethnicity of these 407 thalassemia patients was predominantly Asian or Caucasian. The mean ± SD age was 22.3 ± 13.2 years and patients had received a mean ± SD total number of 149 ± 103.4 units of red blood cells (RBCs). Multiorgan dysfunction was common despite chelation. Twenty-four percent of transfused patients had previous exposure to possible transfusion-associated pathogens including one case of babesia. As 27% were immigrants, the infection source cannot be unequivocally linked to transfusion. Transfusion reactions occurred in 48%, including allergic, febrile, and hemolytic; 19% were alloimmunized. Common antigens were E, Kell, and C. Years of transfusion was the strongest predictor of alloimmunization. Autoantibodies occurred in 6.5% and were associated with alloimmunization (p < 0.0001). Local institutional policies, not patient characteristics, were major determinants of blood preparation and transfusion practices. CONCLUSION: Hemosiderosis, transfusion reactions, and infections continue to be major problems in thalassemia. New pathogens were noted. National guidelines for RBC phenotyping and preparation are needed to decrease transfusion-related morbidity.
BACKGROUND: Transfusions are the primary therapy for thalassemia but have significant cumulative risks. In 2004, the Centers for Disease Control and Prevention (CDC) established a national blood safety monitoring program for thalassemia. This report summarizes the population and their previous nonimmune and immune transfusion complications. STUDY DESIGN AND METHODS: The CDC Thalassemia Blood Safety Network is a consortium of centers longitudinally following patients. Enrollment occurred from 2004 through 2012. Demographics, transfusion history, infectious exposures, and transfusion and nontransfusion complications were summarized. Logistic regression analyses of factors associated with allo- and autoimmunization were employed. RESULTS: The race/ethnicity of these 407 thalassemiapatients was predominantly Asian or Caucasian. The mean ± SD age was 22.3 ± 13.2 years and patients had received a mean ± SD total number of 149 ± 103.4 units of red blood cells (RBCs). Multiorgan dysfunction was common despite chelation. Twenty-four percent of transfused patients had previous exposure to possible transfusion-associated pathogens including one case of babesia. As 27% were immigrants, the infection source cannot be unequivocally linked to transfusion. Transfusion reactions occurred in 48%, including allergic, febrile, and hemolytic; 19% were alloimmunized. Common antigens were E, Kell, and C. Years of transfusion was the strongest predictor of alloimmunization. Autoantibodies occurred in 6.5% and were associated with alloimmunization (p < 0.0001). Local institutional policies, not patient characteristics, were major determinants of blood preparation and transfusion practices. CONCLUSION:Hemosiderosis, transfusion reactions, and infections continue to be major problems in thalassemia. New pathogens were noted. National guidelines for RBC phenotyping and preparation are needed to decrease transfusion-related morbidity.
Authors: William Sievert; Ibrahim Altraif; Homie A Razavi; Ayman Abdo; Ezzat Ali Ahmed; Ahmed Alomair; Deepak Amarapurkar; Chien-Hung Chen; Xiaoguang Dou; Hisham El Khayat; Mohamed Elshazly; Gamal Esmat; Richard Guan; Kwang-Hyub Han; Kazuhiko Koike; Angela Largen; Geoff McCaughan; Sherif Mogawer; Ali Monis; Arif Nawaz; Teerha Piratvisuth; Faisal M Sanai; Ala I Sharara; Scott Sibbel; Ajit Sood; Dong Jin Suh; Carolyn Wallace; Kendra Young; Francesco Negro Journal: Liver Int Date: 2011-07 Impact factor: 5.828
Authors: Michele Lasalle-Williams; Rachelle Nuss; Tuan Le; Laura Cole; Kathy Hassell; James R Murphy; Daniel R Ambruso Journal: Transfusion Date: 2011-02-18 Impact factor: 3.157
Authors: Maxwell Westerman; Arnold Pizzey; Jocelyn Hirschman; Mario Cerino; Yonit Weil-Weiner; Prya Ramotar; Ada Eze; Andrew Lawrie; Gordon Purdy; Ian Mackie; John Porter Journal: Br J Haematol Date: 2008-04-17 Impact factor: 6.998
Authors: Diane M Gubernot; Charles T Lucey; Karen C Lee; Gilliam B Conley; Leslie G Holness; Robert P Wise Journal: Clin Infect Dis Date: 2009-01-01 Impact factor: 9.079
Authors: Sarah J Waldis; Stacey Uter; Donna Kavitsky; Cynthia Flickinger; Sunitha Vege; David F Friedman; Connie M Westhoff; Stella T Chou Journal: Blood Adv Date: 2021-02-09
Authors: Marie E Steiner; Nicole D Zantek; Simon J Stanworth; Robert I Parker; Stacey L Valentine; Leslie E Lehmann; Cassandra D Josephson; Scot T Bateman; Naomi L C Luban Journal: Pediatr Crit Care Med Date: 2018-09 Impact factor: 3.624